Literature DB >> 27508513

Computed Tomography and Magnetic Resonance Enterography in Crohn's Disease: Assessment of Radiologic Criteria and Endpoints for Clinical Practice and Trials.

Parakkal Deepak1, Joel G Fletcher, Jeff L Fidler, David H Bruining.   

Abstract

Early recognition of Crohn's disease with initiation of disease-modifying therapy has emerged as a prominent inflammatory bowel disease management strategy. Clinical practice and trials have often focused on patient symptoms, and more recently, serologic tests, stool inflammatory markers, and/or endoscopic inflammatory features for study entry criteria, treatment targets, disease activity monitoring, and to assess therapeutic response. Unfortunately, patient symptoms do not correlate well with biological disease activity, and endoscopy potentially misses or underestimates disease extent and severity in small bowel Crohn's disease. Computed tomography enterography and magnetic resonance enterography (MRE) are potential tools to identify and quantify transmural structural damage and disease activity in the small bowel. In this review, we discuss the role of computed tomography enterography and MRE in disease management algorithms in clinical practice. We also compare the currently developed MRE-based scoring systems, their strengths and pitfalls, as well as the role for MRE in clinical trials for Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27508513      PMCID: PMC4992454          DOI: 10.1097/MIB.0000000000000845

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  73 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

Review 2.  Review article: biological activity markers in inflammatory bowel disease.

Authors:  D Desai; W A Faubion; W J Sandborn
Journal:  Aliment Pharmacol Ther       Date:  2007-01-08       Impact factor: 8.171

3.  Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent.

Authors:  Alexander Radbruch; Lukas D Weberling; Pascal J Kieslich; Oliver Eidel; Sina Burth; Philipp Kickingereder; Sabine Heiland; Wolfgang Wick; Heinz-Peter Schlemmer; Martin Bendszus
Journal:  Radiology       Date:  2015-04-06       Impact factor: 11.105

4.  Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines.

Authors:  J Panes; Y Bouhnik; W Reinisch; J Stoker; S A Taylor; D C Baumgart; S Danese; S Halligan; B Marincek; C Matos; L Peyrin-Biroulet; J Rimola; G Rogler; G van Assche; S Ardizzone; A Ba-Ssalamah; M A Bali; D Bellini; L Biancone; F Castiglione; R Ehehalt; R Grassi; T Kucharzik; F Maccioni; G Maconi; F Magro; J Martín-Comín; G Morana; D Pendsé; S Sebastian; A Signore; D Tolan; J A Tielbeek; D Weishaupt; B Wiarda; A Laghi
Journal:  J Crohns Colitis       Date:  2013-04-11       Impact factor: 9.071

5.  Non-perforating small bowel Crohn's disease assessed by MRI enterography: derivation and histopathological validation of an MR-based activity index.

Authors:  Michael J Steward; Shonit Punwani; Ian Proctor; Yvette Adjei-Gyamfi; Fiona Chatterjee; Stuart Bloom; Marco Novelli; Steve Halligan; Manuel Rodriguez-Justo; Stuart A Taylor
Journal:  Eur J Radiol       Date:  2011-09-15       Impact factor: 3.528

6.  Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy.

Authors:  Tomonori Kanda; Toshio Fukusato; Megumi Matsuda; Keiko Toyoda; Hiroshi Oba; Jun'ichi Kotoku; Takahiro Haruyama; Kazuhiro Kitajima; Shigeru Furui
Journal:  Radiology       Date:  2015-05-05       Impact factor: 11.105

7.  Benefit of computed tomography enterography in Crohn's disease: effects on patient management and physician level of confidence.

Authors:  David H Bruining; Hassan A Siddiki; Joel G Fletcher; William J Sandborn; Jeff L Fidler; James E Huprich; Jayawant N Mandrekar; William S Harmsen; Paul E Evans; William A Faubion; Karen A Hanson; Steven B Ingle; Darrell S Pardi; Kenneth W Schroeder; William J Tremaine; Edward V Loftus
Journal:  Inflamm Bowel Dis       Date:  2011-02-17       Impact factor: 5.325

8.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).

Authors:  J Y Mary; R Modigliani
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

Review 9.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

10.  Medical therapy of stricturing Crohn's disease: what the gut can learn from other organs - a systematic review.

Authors:  Dominik Bettenworth; Florian Rieder
Journal:  Fibrogenesis Tissue Repair       Date:  2014-03-29
View more
  10 in total

1.  Histopathology Scoring Systems of Stenosis Associated With Small Bowel Crohn's Disease: A Systematic Review.

Authors:  Ilyssa O Gordon; Dominik Bettenworth; Arne Bokemeyer; Amitabh Srivastava; Christophe Rosty; Gert de Hertogh; Marie E Robert; Mark A Valasek; Ren Mao; Satya Kurada; Noam Harpaz; Paula Borralho; Reetesh K Pai; Rish K Pai; Robert Odze; Roger Feakins; Claire E Parker; Tran Nguyen; Vipul Jairath; Mark E Baker; David H Bruining; J G Fletcher; Brian G Feagan; Florian Rieder
Journal:  Gastroenterology       Date:  2019-08-30       Impact factor: 22.682

2.  Predictors of Durability of Radiological Response in Patients With Small Bowel Crohn's Disease.

Authors:  Parakkal Deepak; Joel G Fletcher; Jeff L Fidler; John M Barlow; Shannon P Sheedy; Amy B Kolbe; William S Harmsen; Terry Therneau; Stephanie L Hansel; Brenda D Becker; Edward V Loftus; David H Bruining
Journal:  Inflamm Bowel Dis       Date:  2018-07-12       Impact factor: 5.325

3.  Magnetic resonance enterography features of small bowel Crohn's disease activity: an inter-rater reliability study of small bowel active inflammation in clinical practice setting.

Authors:  Richard Tsai; Aaron Mintz; Michael Lin; Joyce Mhlanga; Adeeti Chiplunker; Amber Salter; Matthew Ciorba; Parakkal Deepak; Kathryn Fowler
Journal:  Br J Radiol       Date:  2019-05-29       Impact factor: 3.039

4.  International consensus to standardise histopathological scoring for small bowel strictures in Crohn's disease.

Authors:  Ilyssa O Gordon; Dominik Bettenworth; Arne Bokemeyer; Amitabh Srivastava; Christophe Rosty; Gert de Hertogh; Marie E Robert; Mark A Valasek; Ren Mao; Jiannan Li; Noam Harpaz; Paula Borralho; Reetesh K Pai; Robert Odze; Roger Feakins; Claire E Parker; Leonardo Guizzetti; Tran Nguyen; Lisa M Shackelton; William J Sandborn; Vipul Jairath; Mark Baker; David Bruining; Joel G Fletcher; Brian G Feagan; Rish K Pai; Florian Rieder
Journal:  Gut       Date:  2021-05-05       Impact factor: 23.059

Review 5.  Role of regenerating islet-derived proteins in inflammatory bowel disease.

Authors:  Jodi-Ann Edwards; Nicholas Tan; Nadlie Toussaint; Peiqi Ou; Cathy Mueller; Albert Stanek; Vladimir Zinsou; Sean Roudnitsky; Michelle Sagal; Lisa Dresner; Alexander Schwartzman; Chongmin Huan
Journal:  World J Gastroenterol       Date:  2020-06-07       Impact factor: 5.742

Review 6.  Treat-to-target in Crohn's disease: Will transmural healing become a therapeutic endpoint?

Authors:  Elena Daniela Serban
Journal:  World J Clin Cases       Date:  2018-10-26       Impact factor: 1.337

7.  Systematic review: outcomes and adverse events from randomised trials in Crohn's disease.

Authors:  Heather Catt; Dyfrig Hughes; Jamie J Kirkham; Keith Bodger
Journal:  Aliment Pharmacol Ther       Date:  2019-03-03       Impact factor: 8.171

8.  Changes in the Management of Patients with Crohn's Disease Based on Magnetic Resonance Enterography Patterns.

Authors:  Evelyn Sayuri S Chinem; Barbara C Esberard; Andre da L Moreira; Tatiana G Barbassa; Guilherme M da Cunha; Antonio Jose de V Carneiro; Heitor S de Souza; Ana Teresa P Carvalho
Journal:  Gastroenterol Res Pract       Date:  2019-12-17       Impact factor: 2.260

Review 9.  Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores.

Authors:  Bruno Lima Rodrigues; Márcia Carolina Mazzaro; Cristiane Kibune Nagasako; Maria de Lourdes Setsuko Ayrizono; João José Fagundes; Raquel Franco Leal
Journal:  World J Gastrointest Endosc       Date:  2020-12-16

Review 10.  Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.

Authors:  Shu-Chen Wei; Ting-An Chang; Te-Hsin Chao; Jinn-Shiun Chen; Jen-Wei Chou; Yenn-Hwei Chou; Chiao-Hsiung Chuang; Wen-Hung Hsu; Tien-Yu Huang; Tzu-Chi Hsu; Chun-Chi Lin; Hung-Hsin Lin; Jen-Kou Lin; Wei-Chen Lin; Yen-Hsuan Ni; Ming-Jium Shieh; I-Lun Shih; Chia-Tung Shun; Yuk-Ming Tsang; Cheng-Yi Wang; Horng-Yuan Wang; Meng-Tzu Weng; Deng-Chyang Wu; Wen-Chieh Wu; Hsu-Heng Yen; Jau-Min Wong
Journal:  Intest Res       Date:  2017-06-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.